Hepatic impairment No dose adjustment is required in sufferers with gentle or average (Little one-Pugh A or B) hepatic impairment (see part five.2). Exposure to midostaurin and its active metabolite CGP62221 is considerably reduced in clients with critical hepatic impairment than that in individuals with standard hepatic operate (see segment 5.has